pubmed-article:3295112 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:3295112 | lifeskim:mentions | umls-concept:C0001818 | lld:lifeskim |
pubmed-article:3295112 | lifeskim:mentions | umls-concept:C0011570 | lld:lifeskim |
pubmed-article:3295112 | lifeskim:mentions | umls-concept:C0020934 | lld:lifeskim |
pubmed-article:3295112 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
pubmed-article:3295112 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
pubmed-article:3295112 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
pubmed-article:3295112 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
pubmed-article:3295112 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
pubmed-article:3295112 | lifeskim:mentions | umls-concept:C1555582 | lld:lifeskim |
pubmed-article:3295112 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:3295112 | pubmed:dateCreated | 1987-7-21 | lld:pubmed |
pubmed-article:3295112 | pubmed:abstractText | Thirty-seven patients participating in a controlled treatment study with imipramine were classified as high or low depressed simultaneously on two depression measures. Analysis of variance by 2 (high-low depressed) X 2 (high-low imipramine dosage) groupings revealed significant dose but no depression main effects. The greater dose effect observed in the low depressed group and the greater response rates found among high-dose patients with low initial depression strongly suggest that the beneficial effect of imipramine in agoraphobia was not primarily antidepressant in nature. | lld:pubmed |
pubmed-article:3295112 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3295112 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3295112 | pubmed:language | eng | lld:pubmed |
pubmed-article:3295112 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3295112 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:3295112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3295112 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:3295112 | pubmed:month | Jun | lld:pubmed |
pubmed-article:3295112 | pubmed:issn | 0022-3018 | lld:pubmed |
pubmed-article:3295112 | pubmed:author | pubmed-author:Mavissakalian... | lld:pubmed |
pubmed-article:3295112 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:3295112 | pubmed:volume | 175 | lld:pubmed |
pubmed-article:3295112 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:3295112 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:3295112 | pubmed:pagination | 358-61 | lld:pubmed |
pubmed-article:3295112 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:3295112 | pubmed:meshHeading | pubmed-meshheading:3295112-... | lld:pubmed |
pubmed-article:3295112 | pubmed:meshHeading | pubmed-meshheading:3295112-... | lld:pubmed |
pubmed-article:3295112 | pubmed:meshHeading | pubmed-meshheading:3295112-... | lld:pubmed |
pubmed-article:3295112 | pubmed:meshHeading | pubmed-meshheading:3295112-... | lld:pubmed |
pubmed-article:3295112 | pubmed:meshHeading | pubmed-meshheading:3295112-... | lld:pubmed |
pubmed-article:3295112 | pubmed:meshHeading | pubmed-meshheading:3295112-... | lld:pubmed |
pubmed-article:3295112 | pubmed:meshHeading | pubmed-meshheading:3295112-... | lld:pubmed |
pubmed-article:3295112 | pubmed:meshHeading | pubmed-meshheading:3295112-... | lld:pubmed |
pubmed-article:3295112 | pubmed:meshHeading | pubmed-meshheading:3295112-... | lld:pubmed |
pubmed-article:3295112 | pubmed:year | 1987 | lld:pubmed |
pubmed-article:3295112 | pubmed:articleTitle | Initial depression and response to imipramine in agoraphobia. | lld:pubmed |
pubmed-article:3295112 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:3295112 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:3295112 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |